Utilized for neurological procedures including biopsies, catheter placement and electrode introduction, the SmartFrame OR Stereotactic System can be combined with preoperative MRI or CT to ensure optimal placement of devices and instruments.
The Food and Drug Adminstration (FDA) has granted 510(k) clearance for the SmartFrame OR Stereotactic System, which reportedly facilitates optimal preoperative placement of instruments and devices for neurological procedures.
Comprised of the SmartFrame OR and the ClearPointer™ Optical Navigation Wand, the SmartFrame OR Stereotactic System can enhance preoperative planning for electrode introduction, catheter placement and brain biopsy procedures, according to ClearPoint Neuro, the manufacturer of the system. The company noted the SmartFrame OR can be combined with preoperative magnetic resonance imaging (MRI) or computed tomography (CT).
Utilized in combination with the SmartFrame OR and a compatible stereotactic optical navigation system, the ClearPointer Optical Navigation Wand facilitates patient registration and navigation, according to ClearPoint Neuro.
“SmartFrame OR embodies over a decade of accumulated expertise in MRI-guided navigation, now enhanced with the latest OR imaging technology,” said Rob Rubio, a segment leader for neuromodulation at ClearPoint Neuro. “It offers surgeons flexible workflows, including iCT forward projection, enabling precise image-based corrections to achieve sub-millimetric accuracy.”
Leading Breast Radiologists Discuss the USPSTF Breast Cancer Screening Recommendations
May 17th 2024In recognition of National Women’s Health Month, Dana Bonaminio, MD, Amy Patel, MD, and Stacy Smith-Foley, MD, shared their thoughts and perspectives on the recently updated breast cancer screening recommendations from the United States Preventive Services Task Force (USPSTF).
Multicenter CT Study Shows Benefits of Emerging Diagnostic Model for Clear Cell Renal Cell Carcinoma
May 15th 2024Combining clinical and CT features, adjunctive use of a classification and regression tree (CART) diagnostic model demonstrated AUCs for detecting clear cell renal cell carcinoma (ccRCC) that were 15 to 22 percent higher than unassisted radiologist assessments.
What a New Meta-Analysis Reveals About Fractional Flow Reserve Assessment with Computed Tomography
May 13th 2024While acknowledging variable accuracy overall with CT-derived fractional flow reserve (FFR-CT) values, researchers found that the accuracy rate increased to 90 percent for FFR-CT values greater > 0.90 and < 0.49.